Pyridostigmine bromide is an orally active cholinesterase inhibitor.
PYRIDOSTIGMINE is indicated for the following:
Pyridostigmine bromide is useful in the treatment of myasthenia gravis.
Published Studies Related to Pyridostigmine
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. [2010.11]
Orthostatic hypotension affects patients with autonomic failure producing considerable disability because of presyncopal symptoms. Severely affected patients may have residual sympathetic tone that can be engaged to increase blood pressure (BP) with the alpha-2 adrenergic antagonist yohimbine.Engaging residual sympathetic tone with yohimbine is a more effective approach to improve orthostatic hypotension as compared with pyridostigmine in patients with severe orthostatic hypotension.
Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. [2009.08]
HIV infection is characterized by persistent immune activation, increased production of proinflammatory cytokines, and rapid T cell turnover...
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2009.07]
3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination... Therefore, we performed a placebo-controlled, double-dummy, double-blind, randomized, crossover study in nine patients with LEMS.
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. [2009.03]
BACKGROUND: There is limited information on medications with promotility effects on the esophagus. Studies in healthy volunteers have shown the potential role of the direct cholinergic agonist bethanechol and the serotonin receptor agonist buspirone in improving esophageal motility. It has been also shown that an acetylcholinesterase inhibitor, the short-acting drug edrophonium administered intravenously caused a greater increase in the esophageal contraction amplitude and duration than bethanechol. Edrophonium cannot be used as a promotility therapy owing to short duration of action and lack of oral administration. The use of another acetylcholinesterase inhibitor pyridostygmine with longer duration of action has not been studied. The aim of the study was to evaluate the effect of oral pyridostygmine (60 mg), buspirone (20 mg), and bethanechol (25 mg) on esophageal function assessed by combined multichannel intraluminal impedance-esophageal manometry... CONCLUSIONS: Oral pyridostygmine, buspirone, and bethanechol enhance esophageal motility with pyridostygmine appearing to have the greatest effect. A potential effect on improving esophageal function and symptoms in patients requires further study.
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. [2008.02]
OBJECTIVE: A subset of fibromyalgia (FM) patients have a dysfunctional hypothalamic-pituitary-insulin-like growth factor 1 (IGF-1) axis, as evidenced by low serum levels of IGF-1 and a reduced growth hormone (GH) response to physiologic stimuli. There is evidence that pyridostigmine (PYD) improves the acute response of GH to exercise in FM patients. The purpose of this study was to evaluate the clinical effectiveness of 6 months of PYD and group exercise on FM symptoms... CONCLUSION: Neither the combination of PYD plus supervised exercise nor either treatment alone yielded improvement in most FM symptoms. However, PYD did improve anxiety and sleep, and exercise improved fatigue and fitness. We speculate that PYD may have improved vagal tone, thus benefiting sleep and anxiety; this notion warrants further study.
Clinical Trials Related to Pyridostigmine
A Pilot Study of Pyridostigmine in Pompe Disease [Not yet recruiting]
Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the
neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant
treatment for people with Pompe disease, as it increases the functional impact of this
Hypothesis: the use of pyridostigmine in Pompe disease will improve transmission of
acetylcholine across the neuromuscular junction, skeletal muscle function, respiratory
function, and quality of life.
Use of Pyridostigmine for Constipation in Diabetics [Completed]
Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the
speed at which food travels through the stomach, intestines and colon, and if pyridostigmine
improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved
by the Food and Drug Administration (FDA) for routine clinical use, however, its use as
proposed in this study is considered investigational.
The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine [Recruiting]
Pyridostigmine is a medication that is used in certain heart rate and blood pressure
conditions. This medication, as a side effect, is known to also cause changes in the
junction between a nerve and muscle. The changes caused at the nerve muscle junction by
pyridostigmine could alter the effect of muscle relaxants (a medication used during surgery
and anesthesia). The investigators are conducting this study to see whether patients taking
pyridostigmine are more or less sensitive to rocuronium (a muscle relaxing medication used
Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients [Completed]
The purpose of the study is to determine if pyridostigmine bromide improves heart rate
variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.
Droxidopa / Pyridostigmine in Orthostatic Hypotension [Recruiting]
The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural
transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
This combination should result in enhanced orthostatic release of NE. The investigators have
already demonstrated that pyridostigmine does not raise supine blood pressure.
Page last updated: 2011-12-09